$7.77
1.02% yesterday
Nasdaq, Sep 08, 10:00 pm CET
ISIN
US98422E1038
Symbol
XERS

Xeris Biopharma Holdings Target price 2025 - Analyst rating & recommendation

Xeris Biopharma Holdings Classifications & Recommendation:

Buy
83%
Hold
17%

Xeris Biopharma Holdings Price Target

Target Price $9.69
Price $7.85
Potential
Number of Estimates 8
8 Analysts have issued a price target Xeris Biopharma Holdings 2026 . The average Xeris Biopharma Holdings target price is $9.69. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 12 analysts: 10 Analysts recommend Xeris Biopharma Holdings to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Xeris Biopharma Holdings stock has an average upside potential 2026 of . Most analysts recommend the Xeris Biopharma Holdings stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 203.07 292.20
23.89% 43.89%
EBITDA Margin -11.23% 11.99%
44.52% 206.79%
Net Margin -27.01% -3.75%
28.90% 86.11%

8 Analysts have issued a sales forecast Xeris Biopharma Holdings 2025 . The average Xeris Biopharma Holdings sales estimate is

$292m
Unlock
. This is
18.77% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$304m 23.38%
Unlock
, the lowest is
$277m 12.61%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $203m 23.89%
2025
$292m 43.89%
Unlock
2026
$352m 20.40%
Unlock
2027
$409m 16.36%
Unlock
2028
$485m 18.46%
Unlock
2029
$581m 19.70%
Unlock
2030
$584m 0.64%
Unlock
2031
$533m 8.76%
Unlock
2032
$582m 9.18%
Unlock

5 Analysts have issued an Xeris Biopharma Holdings EBITDA forecast 2025. The average Xeris Biopharma Holdings EBITDA estimate is

$35.0m
Unlock
. This is
3,335.00% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$39.9m 3,811.76%
Unlock
, the lowest is
$30.1m 2,849.61%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-22.8m 31.26%
2025
$35.0m 253.67%
Unlock
2026
$60.3m 72.05%
Unlock
2027
$124m 106.43%
Unlock

EBITDA Margin

2024 -11.23% 44.52%
2025
11.99% 206.79%
Unlock
2026
17.13% 42.87%
Unlock
2027
30.40% 77.47%
Unlock

8 Xeris Biopharma Holdings Analysts have issued a net profit forecast 2025. The average Xeris Biopharma Holdings net profit estimate is

$-11.0m
Unlock
. This is
65.75% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-1.7m 94.72%
Unlock
, the lowest is
$-25.3m 21.00%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-54.8m 11.92%
2025
$-11.0m 80.01%
Unlock
2026
$36.5m 433.12%
Unlock
2027
$65.8m 80.17%
Unlock

Net Margin

2024 -27.01% 28.90%
2025
-3.75% 86.11%
Unlock
2026
10.38% 376.80%
Unlock
2027
16.07% 54.82%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.37 -0.07
17.78% 81.08%
P/E negative
EV/Sales 4.87

8 Analysts have issued a Xeris Biopharma Holdings forecast for earnings per share. The average Xeris Biopharma Holdings EPS is

$-0.07
Unlock
. This is
66.67% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.01 95.24%
Unlock
, the lowest is
$-0.16 23.81%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.37 17.78%
2025
$-0.07 81.08%
Unlock
2026
$0.23 428.57%
Unlock
2027
$0.41 78.26%
Unlock

P/E ratio

Current -37.00 489.64%
2025
-114.26 208.81%
Unlock
2026
34.31 130.03%
Unlock
2027
19.04 44.51%
Unlock

Based on analysts' sales estimates for 2025, the Xeris Biopharma Holdings stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.79 99.66%
2025
4.87 15.85%
Unlock
2026
4.05 16.95%
Unlock
2027
3.48 14.06%
Unlock
2028
2.94 15.59%
Unlock
2029
2.45 16.46%
Unlock
2030
2.44 0.64%
Unlock
2031
2.67 9.61%
Unlock
2032
2.45 8.41%
Unlock

P/S ratio

Current 5.14 149.28%
2025
4.33 15.80%
Unlock
2026
3.59 16.94%
Unlock
2027
3.09 14.06%
Unlock
2028
2.61 15.59%
Unlock
2029
2.18 16.46%
Unlock
2030
2.16 0.64%
Unlock
2031
2.37 9.61%
Unlock
2032
2.17 8.41%
Unlock

Current Xeris Biopharma Holdings Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Oppenheimer
Locked
Locked
Locked May 09 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 07 2025
Piper Sandler
Locked
Locked
Locked Mar 07 2025
HC Wainwright & Co.
Locked
Locked
Locked Nov 11 2024
Piper Sandler
Locked
Locked
Locked Nov 11 2024
Analyst Rating Date
Locked
Oppenheimer:
Locked
Locked
May 09 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 07 2025
Locked
Piper Sandler:
Locked
Locked
Mar 07 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 11 2024
Locked
Piper Sandler:
Locked
Locked
Nov 11 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today